{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 77 of 129', 'Clinically significant abnormal findings related to vital signs, physical examination, ECGs, or', 'laboratory tests after the first screening visit must be reported as an AE in accordance with', 'Section 11.2; also see Sections 10.4.1 (vital signs), 10.4.2 (physical examination), 10.4.3', '(ECGs), and 10.4.5 (laboratory tests) for further details.', '11.2 Reporting of adverse events', 'AEs reported by the subject or observed by the investigator must be recorded on the AE form', 'of the eCRF and should be described in the following manner:', 'The AE term must be in precise English medical terminology (i.e. not necessarily the exact', 'words used by the subject). Whenever possible, a specific diagnosis should be stated (for', \"example 'allergic contact dermatitis').\", 'The duration of the AE must be reported by the start date and stop date of the event. In', 'addition, it must be recorded whether the AE started prior to start of IMP.', 'AEs must be classified in terms of severity, causality and outcome according to the definitions', 'in Appendix 2: Classification of adverse events.', 'Action taken with trial treatment: Any action taken with IMP or NIMP (TCS) as', 'a', 'consequence of the AE must be recorded (dose not changed, dose reduced, dose increased,', 'drug interrupted, drug withdrawn, not applicable, unknown).', 'Other action taken: any other action taken as a result of the AE must be recorded (none,', 'concomitant medication, concomitant procedure).', 'Withdrawn due to AE: it must be recorded whether the AE leads to withdrawal from the trial.', '11.3 Reporting of serious adverse events', 'The criteria that define an AE as serious (i.e., an SAE) are defined in Appendix 1: Definitions', 'of adverse events and serious adverse events.', '11.3.1 Investigator reporting responsibilities', 'Any SAE must be reported to LEO on the (paper) SAE Form within 24 hours of first', 'knowledge. This report should contain an assessment of available information on seriousness,', 'severity, causal relationship to the IMP or IMP device, causal relationship to NIMP,', 'comparator or trial procedure, the action taken, the outcome to date, and a narrative', 'description of the course of the event.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 78 of 129', 'The completed SAE form must be faxed or scanned and e-mailed to Global', 'Pharmacovigilance, LEO using the e-mail address or fax number below:', 'Global Pharmacovigilance, LEO', 'E-mail address: drug.safety@leo-pharma.com', 'Fax number: +45 7226 3287', 'It may be relevant for the investigator to enclose other information with the SAE form, such', 'as anonymised reports of diagnostic procedures, hospital records, autopsy reports, etc.', 'Additionally, Global Pharmacovigilance, LEO may request further information in order to', 'fully assess the SAE. The investigator must forward such information to LEO upon request by', 'fax or e-mail (see contact details above).', 'The investigator must notify the local institutional review board(s) (IRB independent', 'ethics committee(s) (IEC of SAEs as required by current applicable legislation for the', 'concerned country.', 'SAEs occurring after the completion of the clinical trial (i.e., after the safety follow-up visit at', 'Week 46) should not be routinely sought or collected. However, such events should be', 'reported to LEO (see contact details above) if the investigator becomes aware of them.', '11.3.2 LEO reporting responsibilities', 'Global Pharmacovigilance, LEO is responsible for assessing whether or not an SAE is', 'expected. The relevant reference document for this clinical trial is:', \"For the IMP, the Investigator's Brochure, edition 16 and subsequent updates must be used.\", 'For the NIMP (mometasone furoate, 0.1% cream) the latest version of the approved label', 'must be used.', 'Global Pharmacovigilance, LEO will notify the regulatory authorities and concerned', 'investigators of SAEs according to the current applicable legislation for the concerned', 'countries.', 'The IRB(s)/IEC(s) will be notified of SAEs according to the current applicable legislation for', 'the concerned countries.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}